This study provides preliminary evidence that administration of a single dose of AAV9-GLB1 is safe and well tolerated and suggests that it may lead to biochemical and neuroimaging improvements in Type II GM1 gangliosidosis. This evidence concerns the gene GLB1 and GM1 gangliosidosis.